Appclon Begins Phase 1 Clinical Trial Dosing of CAR-T Therapy for B-cell Non-Hodgkin Lymphoma

[Asia Economy Reporter Chunhee Lee] Appclon announced on the 18th that it has administered the first dose to the first participant in the domestic Phase 1 clinical trial of its autologous chimeric antigen receptor (CAR)-T cell therapy candidate, ‘AT101’.

This clinical trial is being conducted at Seoul Asan Medical Center with 100 patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma. The plan is to complete dosing for all Phase 1 participants within this year. Through this, the efficacy and safety of AT101 after administration will be evaluated to establish the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), and the efficacy of AT101 will be confirmed with a single dose in Phase 2 clinical trials.

An Appclon representative stated, "AT101 uses the world’s only 1218 antibody developed in-house, which acts on a new epitope of the CD19 disease protein," adding, "We expect it to show differentiated effects compared to existing CAR-T therapies."